CURATE: A Cancer Research UK Phase I/II, Dose Escalation and Expansion Trial of TT-702, A Selective Adenosine A2BR Antagonist, Given Orally as a Monotherapy Agent and in Combination, in Patients With Advanced Solid Tumours
Latest Information Update: 16 May 2024
At a glance
- Drugs TT 702 (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms CURATE
- 09 May 2024 Planned number of patients changed from 114 to 188.
- 09 May 2024 Planned End Date changed from 1 Sep 2025 to 1 Jun 2027.
- 09 May 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Jun 2027.